|
|
|
|
Office Locations:
|
Lilly Corporate Center
Indianapolis, IN 46285
Phone: 800-545-5979
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. As of 2022, Lilly is known for its clinical depression drugs Prozac (fluoxetine) (1986) and Cymbalta (duloxetine) (2004) and antipsychotic medication Zyprexa (olanzapine) (1996), though its primary revenue drivers are diabetes drugs Humalog (insulin lispro) (1996) and Trulicity (dulaglutide) (2014). Eli Lilly and Company (NYSE: LLY) today announced (January 2021) a $30 million limited partner investment in Unseen Capital Health Fund LP, a newly-formed venture fund created by racially diverse and historically underrepresented business leaders. For over 140 years, 100 medicines have been discovered.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
|
| Hadrian Szpurka | |
| |
Senior Director | |
| Katie Hewitt | |
| |
Chief Business Officer | |
| Leigh Ann Pusey | |
| |
Executive Vice President | |
|
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
11/18/2024
|
Revisto
|
TX
|
$4,000,000
|
Seed
|
11/13/2024
|
TRexBio
|
CA
|
$84,000,000
|
Series B
|
10/17/2024
|
Aktis Oncology
|
MA
|
$175,000,000
|
Series B
|
10/17/2024
|
Superluminal Medicines
|
MA
|
$120,000,000
|
Series A
|
10/16/2024
|
Sunbird Bio
|
MA
|
$14,000,000
|
|
10/09/2024
|
Arda Therapeutics
|
CA
|
$43,000,000
|
Series A
|
10/09/2024
|
Amprion
|
CA
|
$6,000,000
|
Series B
|
09/06/2024
|
OrsoBio
|
CA
|
$67,000,000
|
Series B
|
05/23/2024
|
Radar Therapeutics
|
CA
|
$13,400,000
|
Seed
|
03/13/2024
|
Zephyr
|
TX
|
$111,000,000
|
Series A
|
|
|
|
|
|
|
|
